Skip to content
Companies

Porosome Therapeutics

Therapies that restore the cell's secretory machinery

Raised to date

$3.6M

across 1 Form D filing

Investors
7
Last filed
Mar 24, 2026

About

Porosome Therapeutics is a Boston-based preclinical biopharmaceutical company built around the porosome, the cell's universal secretory machinery. It develops therapies that either reconstitute functional porosomes into diseased cells or target previously undruggable porosome proteins with small molecules and peptides. Its programs span Alzheimer's disease, cystic fibrosis, type 1 and type 2 diabetes, and lung cancer, and it received FDA orphan drug designation for its cystic fibrosis program in 2025. AI-driven small molecule discovery runs through its Porosome.AI LLC subsidiary and the Alzheimer's work through its NeuroTher LLC subsidiary.

The first company to build a drug discovery platform dedicated to the porosome, opening a target class treated as undruggable and letting one mechanism address diseases as different as Alzheimer's, cystic fibrosis and diabetes.

Funding

  • EquityFiled Mar 24, 2026Form D/A
    $3.6M/ no target

Product

Porosome reconstitution therapy

Preclinical therapeutic platform

A first-in-class, disease-modifying biologic approach that introduces functional porosomes into the plasma membrane of diseased cells to restore normal secretion, combined in the lead program with a small-molecule flavonoid.

  • Restores secretion by reconstituting the cell's native secretory machinery
  • Preclinical evidence in Alzheimer's human brain organoids, including Tau reduction
  • Cystic fibrosis program reported restoring mucin secretion more effectively than TRIKAFTA in assays, with FDA orphan drug designation in 2025

Built for

Patients with diseases of secretory dysfunction, reached through pharmaceutical partners and eventually prescribing clinicians in neurology, pulmonology and endocrinology

People on file